Application of Defined Approaches to Assess Skin Sensitization Potency of Isothiazolinone Compounds.
LLNA
artificial neural network
nonanimal methodology
point of departure
risk assessment
skin sensitization
Journal
Applied in vitro toxicology
ISSN: 2332-1512
Titre abrégé: Appl In Vitro Toxicol
Pays: United States
ID NLM: 101692723
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
entrez:
17
1
2023
pubmed:
18
1
2023
medline:
18
1
2023
Statut:
ppublish
Résumé
Isothiazolinones (ITs) are widely used as antimicrobial preservatives in cosmetics and as additives for preservation of consumer and industrial products to control bacteria, fungi, and algae. Although they are effective biocides, they have the potential to produce skin irritation and sensitization, which poses a human health hazard. In this project, we evaluated nonanimal defined approaches (DAs) for skin sensitization that can provide point-of-departure estimates for use in quantitative risk assessment for ITs. The skin sensitization potential of six ITs was evaluated using three internationally harmonized nonanimal test methods: the direct peptide reactivity assay, KeratinoSens™, and the human cell line activation test. Results from these test methods were then applied to two versions of the Shiseido Artificial Neural Network DA. Sensitization hazard or potency predictions were compared with those of the in vivo murine local lymph node assay (LLNA). The nonanimal methods produced skin sensitization hazard and potency classifications concordant with those of the LLNA. EC3 values (the estimated concentration needed to produce a stimulation index of three, the threshold positive response) generated by the DAs had less variability than LLNA EC3 values, and confidence limits from the DAs overlapped those of the LLNA EC3 for most substances. The application of
Identifiants
pubmed: 36647556
doi: 10.1089/aivt.2022.0014
pii: 10.1089/aivt.2022.0014
pmc: PMC9814110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117-128Informations de copyright
Copyright 2022, Mary Ann Liebert, Inc., publishers.
Déclaration de conflit d'intérêts
D.G.A., J.S., and J.T. are employed by Inotiv, Inc. V.J.J. is employed by Burleson Research Technologies, Inc. T.G. was employed by Burleson Research Technologies, Inc., at the time of the in vitro laboratory work and is now employed by Torque Bio, Inc. The remaining authors, A.L., D.G., T.D., J.F., M.P., T.M., N.K., and S.S., declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Toxicol In Vitro. 2016 Aug;34:220-228
pubmed: 27085510
J Appl Toxicol. 2015 Nov;35(11):1333-47
pubmed: 25824844
Int J Toxicol. 2021 Jul-Aug;40(1_suppl):5S-19S
pubmed: 34259065
Contact Dermatitis. 1999 Mar;40(3):150-4
pubmed: 10073443
Contact Dermatitis. 2013 Nov;69(5):261-2
pubmed: 24117736
Arch Toxicol. 2012 Aug;86(8):1273-95
pubmed: 22707154
Cutan Ocul Toxicol. 2007;26(2):135-45
pubmed: 17612980
Regul Toxicol Pharmacol. 2008 Oct;52(1):39-45
pubmed: 18423821
Eur J Dermatol. 2017 Apr 1;27(2):115-122
pubmed: 28174143
J Appl Toxicol. 2015 Nov;35(11):1318-32
pubmed: 25820183
Crit Rev Toxicol. 2018 May;48(5):359-374
pubmed: 29474122
Regul Toxicol Pharmacol. 2003 Dec;38(3):269-90
pubmed: 14623479
Crit Rev Toxicol. 2018 May;48(5):344-358
pubmed: 29474128
J Allergy (Cairo). 2011;2011:424203
pubmed: 21747867
Regul Toxicol Pharmacol. 2015 Jul;72(2):350-60
pubmed: 25981449
Regul Toxicol Pharmacol. 2008 Oct;52(1):3-23
pubmed: 18406028
Int J Toxicol. 2021 Jul-Aug;40(1_suppl):20S-33S
pubmed: 34259066
Arch Toxicol. 2016 Dec;90(12):2861-2883
pubmed: 27629427
Dermatitis. 2005 Dec;16(4):157-202
pubmed: 16536334